Advanced Search (Items only)
Tags: 2013, Bassett R L, BRAF, Bucheit A D, Cancer, clinical features, Curry J L, dabrafenib, Davies M A, dose-escalation trial, Gershenwald J E, Hwu P, improved, Jakob J A, Journal Article or Conference Abstract Publication, Kim K B, Lazar A J, mek inhibitor trametinib, Melanoma, multicenter, NRAS, oncology, open-label, prognostic factor, selumetinib, stage IV, Survival, Syklawer E, v600e, vemurafenib
atom, dcmes-xml, json, omeka-xml, rss2